Seastar Medical Holding Corp. was granted a third breakthrough device designation by the U.S. FDA for its Selective Cytopheretic device (SCD), a biomimetic membrane-based device used to treat patients with acute inflammatory conditions, which can cause organ failure and death. The latest designation is for its use in patients with hepatorenal syndrome. It follows other indications including cardiorenal syndrome and in adults with acute kidney injury (AKI).
Researchers from Anhui Medical University (AMU) presented data from a study that aimed to assess the role of gastrin-releasing peptide (GRP) and its receptor GRPR in acute kidney injury (AKI).
Micurx Pharmaceuticals Inc. has patented peptide-drug conjugates consisting of peptide targeting kidney cells covalently linked to an anti-inflammatory or immunomodulating or nephron-protective drug through a linker reported to be useful for the treatment of acute kidney injury, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
The U.S. FDA has cleared the way for Seastar Medical Holding Corp.. to conduct a pivotal IDE study of its Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). The Denver-based company plans to begin enrolling patients as early as next month.
Cardiorenal Systems Inc. has scored a U.S. FDA breakthrough device designation for technology to prevent patients undergoing cardiac surgery from developing acute kidney injury (AKI). AKI is reported in up to 30% of approximately 780,000 cardiac surgeries performed each year in the U.S., Europe and the Middle East, complicating patient recovery, prolonging ICU hospitalization and contributing to patient mortality after surgery.
Researchers from Cincinnati Children’s Hospital Medical Center have published data from a study that aimed to investigate the role of interleukin-33 (IL-33) in cardiac remodeling after acute kidney injury (AKI).
Scientists in Edinburgh are planning a clinical trial of licensed drugs in the prevention of chronic kidney disease (CKD) following acute kidney injury (AKI), after uncovering a new mechanism linking the pathology of one with the other. It has only recently been recognized that AKI is linked to CKD and cardiovascular disease, and to date the molecular pathways that control the transition are not well-mapped. As a result, there are no therapies for preventing acute injury progressing to chronic disease.
Revelation Biosciences Inc. announced positive results for REVTx-300 in a preclinical model of acute kidney injury (AKI), a type of chronic kidney disease (CKD).
Klotho Therapeutics Inc. has synthesized new histone deacetylase 8 (HDAC8) inhibitors reported to be useful for the treatment of acute kidney injury and chronic kidney disease.
The U.S. FDA has granted breakthrough device designation to Potrero Medical Inc. for its AKI Predict machine learning algorithm for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in intensive care patients recovering from cardiac surgery.